

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 08:48:18 ON 06 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

DICTIONARY FILE UPDATES: 5 SEP 2006 HIGHEST RN 905905-44-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-753261.str



chain nodes :

20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

8-10 11-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15 14-16 15-18 16-17 17-18

exact/norm bonds :

5-7 6-9 7-8 8-9 14-16 15-18 16-17 17-18

exact bonds :

8-10 11-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS

L1 STRUCTURE UPLOADED

=> C


C IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 08:48:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 939 TO ITERATE

100.0% PROCESSED 939 ITERATIONS

113 ANSWERS

SEARCH TIME: 00.00.01

L2 113 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.36

FILE 'CAPLUS' ENTERED AT 08:48:38 ON 06 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Sep 2006 VOL 145 ISS 11
FILE LAST UPDATED: 5 Sep 2006 (20060905/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2

L3 3 L2

=> d fbib abs hitstr tot

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:791806 CAPLUS
 DN 145:217964
 TI Crystalline 7-[[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl-1H-imidazo[4,5-b]pyridin-5-amine sulfate trihydrate and its pharmaceutical uses
 IN Chase, Charles E.; Kushida, Ikuro
 PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 45pp.
 CODEN: PIXX22
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006083908	A1	20060810	WO 2006-US3463	20060201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006194833	A1	20060831	US 2005-648701P	P 20050202
			US 2006-344534	20060201
			US 2005-648701P	P 20050202

AB The invention relates to crystalline 7-[[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl-1H-imidazo[4,5-b]pyridin-5-amine sulfate trihydrate (E 6070), its method of preparation, and its therapeutic uses.

Pharmaceutical compns. containing crystalline E 6070 and an acceptable carrier represent one

embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E 6070.

The compound was prepared and characterized by x-ray diffraction studies. IT 512391-43-8P, E 6070

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOU (Biological study); PREP (Preparation); USES (Uses) (crystalline)


(cyclohexylmethylamino)methylindolylmethylimidazopyridinamine and its pharmaceutical uses

RN 512391-43-8 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl-, sulfate (1:1), trihydrate (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CH 1
 CRN 512391-42-7
 CMF C23 H28 N6




CH 2

CRN 7664-93-9
 CMF H2 O4 S



IT 512391-42-7, ER 807447
 RL: RCT (Reactant); RACT (Reactant or reagent) (crystalline)
 (cyclohexylmethylamino)methylindolylmethylimidazopyridinamine and its pharmaceutical uses

RN 512391-42-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:780361 CAPLUS
 DN 141:295778
 TI Preparation of deazapurines for use in pharmaceutical compositions for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
 IN Daun, Jane; Fields, Scott; Kobayashi, Seiichi
 PA Eisai Co., Ltd., Japan
 SO U.S. Pat. Appl., 178 pp., Cont.-in-part of WO 2003 57,696.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004186127	A1	20040923	US 2004-753261	20040107
			US 2002-346598P	P 20020107
			US 2003-US366	A2 20030107
WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-346598P	P 20020107

PATENT FAMILY INFORMATION:

FAN 2003:551516


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-346598P	P 20020107
CA 2472479	AA	20030717	CA 2003-2472479	20030107
			US 2002-346598P	P 20020107
AU 2003235741	A1	20030724	WO 2003-US366	20030107
			AU 2003-235741	20030107
			US 2002-346598P	P 20020107
BR 2003006785	A	20041109	BR 2003-6785	20030107
			US 2002-346598P	P 20020107
			WO 2003-US366	20030107
EP 1474425	A1	20041110	EP 2003-729359	20030107
EP 1474425	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			US 2002-346598P	P 20020107

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US	NO	DATE	US	NO	DATE	US	NO	DATE	US	NO	DATE
US 2005124649	A1	20050609	US 2003-500840	20030107	US 2002-346598P	P	20020107	US 2003-500840	20030107	US 2002-346598P	P
CN 1630657	A	20050622	CN 2003-805508	20030107	US 2002-346598P	P	20020107	CN 2003-805508	20030107	US 2002-346598P	P
JP 2005524621	T2	20050818	JP 2003-558011	20030107	US 2002-346598P	P	20020107	JP 2003-558011	20030107	US 2002-346598P	P
AT 327236	E	20060615	AT 2003-729359	20030107	US 2002-346598P	P	20020107	AT 2003-729359	20030107	US 2002-346598P	P
WO 2004063336	A2	20040729	WO 2002-346598P	20020107	WO 2004-US293		20040107	WO 2004-US293	20040107		
WO 2004063336	A3	20040826									
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW											
US 2004186127	A1	20040923	US 2004-753261	20040107	US 2002-346598P	P	20020107	US 2004-753261	20040107	US 2002-346598P	P
ZA 2004006272	A	20051116	ZA 2004-6272	20040805	US 2002-346598P	P	20020107	ZA 2004-6272	20040805	US 2002-346598P	P
NO 2004003290	A	20040922	NO 2004-3290	20040806	US 2002-346598P	P	20020107	NO 2004-3290	20040806	US 2002-346598P	P
			US 2002-346598P	20020107	WO 2003-US366	20030107					

OS MARPAT 141:295778

GI




AB Deazapurines, such as I (R1 = H, NH2, NHMe, NHAc, OH, F, OMe, CN, NHC(=O)Et; R2 = H, NRRaRb, ORa, aliphatic, heteroaliph., aryl, heteroaryl, etc.; Ra, Rb =

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
H, aliph., heteroaliph., aryl, heteroaryl; R3 = H, CN, halogen, heteroaryl, amino, carbonyl, etc.], were prepd. for treatment of reperfusion injuries, osteoporosis and/or bone metastasis. Thus, deazapurine II was prepd. via a multistep synthetic sequence starting from
Me indole-5-carboxylate, di-tert-Bu dicarbonate, tributylstannane, 5,6-diamino-4-chloro-2-pyridinyl-carbamic acid Et ester, tri-Et orthocarbonate, and phthalimide. The prepd. deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC)
IT 761458-54-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ER 809047; preparation of deazapurines for use in pharmaceutical compns.

for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)
RN 761458-54-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 562083-98-1
CMF C16 H13 N5 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 562083-93-6P


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
562083-44-7P 562083-46-9P 562083-49-2P
562083-50-5P 562083-83-4P 562083-84-5P
562083-94-7P 562083-99-2P 562084-05-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)
RN 561307-06-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 561307-07-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[3-chlorophenyl]methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562077-48-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)


RN 562083-93-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[1E]-2-cyclohexylethenyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 561307-06-0P, ER 806274 561307-07-1P, ER 805094
562077-48-9P 562077-49-0P 562077-50-3P
562077-51-4P 562077-52-5P 562077-53-6P
562077-54-7P 562077-55-8P 562077-56-9P
562077-57-0P 562077-59-2P 562077-61-6P
562077-97-8P 562078-00-6P 562078-08-4P
562078-10-8P 562078-35-7P 562078-70-0P
562079-06-5P 562079-30-5P 562079-63-4P
562079-95-2P 562080-38-0P 562080-50-6P
562081-01-0P, ER 806333 562081-02-1P
562081-16-7P 562081-19-0P 562081-25-8P
562081-26-9P 562081-27-0P 562081-28-1P
562081-31-6P 562081-32-7P 562081-59-8P
562081-60-1P 562081-61-2P 562081-62-3P
562081-63-4P 562081-64-5P 562081-67-8P
562081-83-8P 562081-88-3P 562081-89-4P
562081-90-7P 562081-91-8P 562081-92-9P
562081-93-0P 562081-94-1P 562081-95-2P
562081-96-3P 562081-97-4P, ER 806820
562081-98-5P 562082-38-6P 562082-59-1P
562082-68-2P 562082-85-3P 562082-86-4P
562082-87-5P 562082-88-6P 562082-89-7P
562082-90-0P 562082-91-1P 562082-92-2P, ER 806987 562082-93-3P 562082-94-4P, ER 807140
562082-95-5P 562082-96-6P 562082-97-7P
562082-98-8P 562083-00-5P 562083-01-6P
562083-02-7P 562083-04-9P 562083-39-0P
562083-41-4P 562083-42-5P 562083-43-6P


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 562077-49-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-50-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethyl-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)



RN 562077-51-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 562077-52-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-butyl-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 562077-53-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 562077-54-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 562077-55-8 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-56-9 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethoxy-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-57-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[(4-methylphenyl)methyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-59-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[4-(methylthio)phenyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-61-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-methoxyphenyl)-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-97-8 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(1-piperidinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562078-00-6 CAPLUS
 CN Piperazine, 1-acetyl-4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562078-08-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-methoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562078-10-8 CAPLUS
 CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl]phenyl- (9CI) (CA INDEX NAME)




RN 562078-35-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[bis(2-methoxyethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562078-70-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562079-06-5 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562079-30-5 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(3,4,5-trimethoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-63-4 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-phenylethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562079-95-2 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[2-(2-pyridinyl)ethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562080-38-0 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[4-chlorophenyl]methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562080-50-6 CAPLUS
CN Butanamide, 2-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-4-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-01-0 CAPLUS
CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-02-1 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[ethyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-16-7 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[ethyl(phenylamino)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-19-0 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-25-8 CAPLUS
CN Benzenesulfonamide, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 562081-26-9 CAPLUS
CN Benzenepropanamide, alpha-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-27-0 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-28-1 CAPLUS
CN 1H-Indole-3-propanamide, 2-methyl-7-[5-[(phenylamino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-31-6 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl] (4-methoxyphenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-32-7 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl] (4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-59-8 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl] (4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-60-1 CAPLUS
CN 1H-Indole-3-propanamide, 2-methyl-7-[5-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl] (4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-61-2 CAPLUS
CN 1H-Indole-3-propanamide, 2-methyl-7-[5-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl] (4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562081-62-3 CAPLUS
CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-63-4 CAPLUS
CN 1H-Indole-3-propanamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-64-5 CAPLUS
CN 1H-Indole-3-propanamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 562081-67-8 CAPLUS
CN Glycine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 562081-83-8 CAPLUS
CN 1H-Indole-3-propanamide, N-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-88-3 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1R)-1-phenylethylamino]methyl]-1H-indol-2-yl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-89-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1S)-1-phenylethylamino]methyl]-1H-indol-2-yl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-93-0 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethylamino)-1-[(ethylphenylamino)methyl]-2-oxoethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-94-1 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethylamino)-1-[(ethylphenylamino)methyl]-2-oxoethyl]]- (9CI) (CA INDEX NAME)




RN 562081-95-2 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethoxymethyl)-1-(ethoxymethyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-90-7 CAPLUS
 CN Piperazine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 562081-91-8 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-92-9 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-methoxyphenyl)methyl]methyl]amino]]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-96-3 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-97-4 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-98-5 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-38-6 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(3-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-59-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-68-2 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-[(methyl(phenylmethyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-88-6 CAPLUS
CN Piperidine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 562082-89-7 CAPLUS
CN Morpholine, 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 562082-90-0 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[(2-chlorophenyl)methyl]methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-85-3 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]methyl]-4-piperidinyl](4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562082-86-4 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-87-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1R)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-91-1 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[(4-chlorophenyl)methyl]methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-92-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-93-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-94-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 7-[5-[[[(4-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-95-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-((5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-((2-methoxyphenyl)methyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-96-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 7-[5-[[[(2-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-01-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[(2-(trifluoromethoxy)phenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-02-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 7-[5-[[[(2-furanylmethyl)methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-04-9 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-[[[2-((5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl)methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-97-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[(3-(trifluoromethoxy)phenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-98-8 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[(4-(trifluoromethoxy)phenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-00-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-39-0 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 2-methyl-7-[5-[[[(12Z)-2-phenylethenyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 562083-41-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 2-methyl-7-[5-[[[(2-phenylethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-42-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-((5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl)methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-43-6 CAPLUS
 CN L-Alanine,
 N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562083-44-7 CAPLUS
 CN Benzamide,
 N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-46-9 CAPLUS
 CN Benzamide,
 N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-84-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[5-[(cyclohexylsulfonyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562083-94-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 7-[[5-[(2-cyclohexylethyl)-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-99-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562084-05-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[methyl(4-


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-49-2 CAPLUS
 CN Cyclohexanone, 4-[[[2-(5-amino-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 562083-50-5 CAPLUS
 CN Cyclohexanone,
 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 562083-83-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[5-[(cyclohexylsulfonyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 methylenecyclohexyl]amino]methyl]-1H-indol-2-yl)- (9CI) (CA INDEX NAME)




IT 562083-81-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)
 RN 562083-81-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine,
 7-[[5-[(cyclohexylthio)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




IT 561307-19-5P 562083-10-7P 562083-34-5P
 562083-35-6P 562083-36-7P 562083-37-8P
 562083-38-9P 562083-47-0P 562083-59-4P
 562083-74-3P 562083-90-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)
 RN 561307-19-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[[5-[[[1,1-dimethylethyl]dimethylethyl]oxy]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-10-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[4-(trifluoromethyl)phenoxy]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-34-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylthio)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-35-6 CAPLUS
 CN 4-Piperidinone, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-47-0 CAPLUS
 CN Cyclohexanone, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 562083-59-4 CAPLUS
 CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 562083-74-3 CAPLUS
 CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-1-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-36-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1-oxido-4-thiomorpholinyl)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-37-8 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylmethoxy)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-38-9 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(phenylethynyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-90-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(3-cyclohexen-1-yl)methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AN 2003:551516 CAPLUS
 DN 139:117268
 TI Preparation of deazapurines for use in pharmaceutical compositions for the treatment of inflammatory, autoimmune and proliferative diseases
 IN Daun, Jane; Davis, Heather A.; Gusovsky, Fabian; Hishinuma, Ieharu; Jiang, Yimin; Kaneko, Toshihiko; Kikuchi, Kouichi; Kobayashi, Seichi; Lescaarbeu, Andre; Li, Xiang-Li; Muramoto, Kenzo; Ohi, Norihito; Pesant, Marc; Seletsky, Boris M.; Soejima, Morohiko; Yao, Ye; Yokohama, Hiromitsu; Zhao, Janet Y.; Zheng, Wanjun; Tremblay, Lynda
 PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472479	AA	20030717	CA 2003-2472479	20030107
AU 2003235741	A1	20030724	AU 2003-235741	20030107
BR 2003006785	A	20041109	BR 2003-6785	20030107
EP 1474425	A1	20041110	EP 2003-1474425	20030107
EP 1474425	B1	20060524	EP 2003-1474425	20030107
R: AT, BE, CH, DE, DK, EE, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, ES, HU, SK				
US 2005124649	A1	20050609	US 2003-124649	20030107
CN 1630657	A	20050622	CN 2003-1630657	20030107
JP 2005542621	T2	20050818	JP 2003-558011	20030107
			US 2002-346598P	20020107
			WO 2003-US366	20030107

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AT 327236 E 20060615 AT 2003-729359 20030107
 WO 2004063336 A2 20040729 US 2002-346598P P 20020107
 WO 2004063336 A3 20040826 US 2004-US293 20040107
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ
 US 2004186127 A1 20040923 WO 2003-US366 A 20030107
 US 2002-346598P P 20020107
 WO 2003-US366 A2 20030107
 ZA 2004006272 A 20051116 ZA 2004-6272 20040805
 US 2002-346598P P 20020107
 NO 2004003290 A 20040922 NO 2004-3290 20040806
 US 2002-346598P P 20020107
 WO 2003-US366 W 20030107


PATENT FAMILY INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004186127	A1	20040923	US 2004-753261	20040107
			US 2002-346598P	20020107
			WO 2003-US366	20030107
WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
OS MARPAT 139:117268			US 2002-346598P	20020107
GI				




AB Indolyldeazapurines, such as I [R1 = H, NH2, alkylamino, acylamino, etc.; R2 = H, amino, alkoxy, alkyl, etc.; R3 = H, CN, halogen, heteroaryl,

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 amino, carbamoyl, etc.), were prepd. for therapeutic use as inhibitors of cell adhesion, mol. expression and inflammatory cytokine signal transduction. These deazapurines are useful in the treatment of inflammatory, autoimmune, proliferative, central nervous system and cardiovascular diseases, such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, asthma, psoriasis, allograft rejection/graft vs. host disease, idiopathic thrombocytopenia, allergic rhinitis, atopic dermatitis, systemic lupus, glomerulonephritis, diabetes, ulcerative colitis/Crohn's disease, erythematous, eczema, urticaria, myasthenia gravis, idiopathic thrombocytopenia purpura and cancer. Thus, deazapurine II was prepd. via a coupling reaction of the corresponding halodeazapurine with 2-(tributylstannyl)-1H-indole-1-carboxylic acid 1,1-dimethylethyl ester. The prepd. deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC).
 IT 562081-62-3P, ER 806393 562083-38-9P, ER 806644
 562083-47-0P, ER 807586 562083-59-4P, ER 807790
 562083-81-2P, ER 808036 562083-93-6P, ER 808281
 562084-05-3P, ER 807835
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indolyldeazapurines for use in pharmaceutical compns. for the treatment of inflammatory, autoimmune and proliferative diseases)
 RN 562081-62-3 CAPLUS
 CN L-Alanine.
 N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 562083-38-9 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine,
 2-methyl-7-[5-(phenylethynyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-47-0 CAPLUS
 CN Cyclohexanone,
 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 562083-59-4 CAPLUS
 CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 562083-81-2 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine,
 7-[5-[(cyclohexylthio)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-93-6 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[5-[[1E]-2-cyclohexylethenyl]-1H-indol-
2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 562084-05-3 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(4-
methylenecyclohexyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




IT 561307-06-0P 561307-07-1P 562077-48-9P, ER
806014 562077-49-0P, ER 806006 562077-50-3P, ER 805985
562077-51-4P, ER 805984 562077-52-5P, ER 806002
562077-53-6P, ER 805969 562077-54-7P, ER 805971
562077-55-8P, ER 806007 562077-56-9P, ER 806011
562077-57-0P, ER 805972 562077-59-2P, ER 805997
562077-61-6P, ER 806010 562077-97-8P, ER 806123
562078-00-6P, ER 806136 562078-08-4P, ER 806221


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 561307-07-1 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[5-[[[3-chlorophenyl]methyl]methylami
no]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562077-48-9 CAPLUS
CN 1H-indole-5-carbonitrile, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-
yl)- (9CI) (CA INDEX NAME)



RN 562077-49-0 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

562078-10-8P, ER 806220 562078-15-7P, ER 806224
562078-70-0P, ER 806228 562079-06-5P, ER 806276
562079-10-5P, ER 806275 562079-63-4P, ER 806273
562079-95-2P, ER 806317 562080-38-0P, ER 806320
562080-50-6P, ER 806329 562081-01-0P, ER 806333
562081-02-1P, ER 806336 562081-16-7P, ER 806358
562081-19-0P, ER 806359 562081-25-8P, ER 806363
562081-26-9P, ER 806362 562081-27-0P, ER 806361
562081-28-1P, ER 806368 562081-31-6P, ER 806372
562081-32-7P, ER 806373 562081-59-8P, ER 806374
562081-60-1P, ER 806375 562081-61-2P, ER 806383
562081-63-4P, ER 806402 562081-64-5P, ER 806417
562081-67-8P, ER 806419 562081-83-8P, ER 806421
562081-88-3P, ER 806435 562081-89-4P, ER 806437
562081-90-7P, ER 806569 562081-91-8P, ER 806609
562081-92-9P, ER 806610 562081-93-0P, ER 806647
562081-94-1P, ER 806653 562081-95-2P, ER 806671
562081-96-3P, ER 806790 562081-97-4P, ER 806820
562081-98-5P, ER 806839 562082-38-6P, ER 806840
562082-59-1P, ER 806841 562082-68-2P, ER 806842
562082-85-3P, ER 806843 562082-86-4P, ER 806844
562082-87-5P, ER 806860 562082-88-6P, ER 806901
562082-89-7P, ER 806902 562082-90-0P, ER 806903
562082-91-1P, ER 806905 562082-92-2P, ER 806987
562082-93-3P, ER 807014 562082-94-4P, ER 807140
562082-95-5P, ER 807183 562082-96-6P, ER 807240
562082-97-7P, ER 807450 562082-98-8P, ER 807451
562083-00-5P, ER 807452 562083-01-6P, ER 807460
562083-02-7P, ER 807573 562083-04-9P, ER 806286
562083-10-7P, ER 806287 562083-14-5P, ER 806311
562083-15-6P, ER 806355 562083-16-7P, ER 806401
562083-17-8P, ER 806404 562083-19-0P, ER 806645
562083-41-4P, ER 806646 562083-42-5P, ER 806095
562083-43-6P, ER 806420 562083-44-7P, ER 806432
562083-46-9P, ER 807313 562083-49-2P, ER 807759
562083-50-5P, ER 807789 562083-74-3P, ER 807837
562083-83-4P, ER 808082 562083-84-5P, ER 808083
562083-85-6P, ER 808103 562083-87-8P, ER 808040
562083-90-3P, ER 808128 562083-94-7P, ER 808469
562083-98-1P, ER 809047 562083-99-2P, IC 261
562084-00-8P, IC 395 562084-01-9P, IC 375
562084-02-0P, IC 380 562084-03-1P, IC 416
562084-04-2P, ER 807546

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of indolyldeazapurines for use in pharmaceutical compns. for
the treatment of inflammatory, autoimmune and proliferative diseases)


RN 561307-06-0 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-
[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX
NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 562077-50-3 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-ethyl-7-(1H-indol-2-yl)- (9CI) (CA
INDEX NAME)




RN 562077-51-4 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-propyl- (9CI) (CA
INDEX NAME)



RN 562077-52-5 CAPLUS

CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-butyl-7-(1H-indol-2-yl)- (9CI) (CA
INDEX NAME)




RN 562077-53-6 CAPLUS


CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-54-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-((1H-indol-2-yl)-2-((4-methylphenyl)methyl)- (9CI) (CA INDEX NAME)




RN 562077-55-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-([5-(4-morpholinylmethyl)-1H-indol-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-56-9 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethoxy-7-([5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-57-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-((4-methylphenyl)methyl)-7-([5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-59-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-([4-(methylthio)phenyl]-7-([5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-61-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-methoxyphenyl)-7-([5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562077-97-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-([5-(1-piperidinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562078-00-6 CAPLUS
CN Piperazine, 1-acetyl-4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562078-00-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-([5-[[[4-(methoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562078-10-8 CAPLUS
CN Methanone, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl]phenyl)- (9CI) (CA INDEX NAME)




RN 562078-35-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-([5-[[[bis(2-methoxyethyl)amino]methyl]-1H-indol-2-yl]-2-methyl)- (9CI) (CA INDEX NAME)




RN 562078-70-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-([5-[[[methyl(2-(2-pyridinyl)ethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562079-06-5 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562079-30-5 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(3,4,5-trimethoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-63-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-phenylethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562079-95-2 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[2-(2-pyridinyl)ethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562080-38-0 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[2-(4-chlorophenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562080-50-6 CAPLUS
 CN Butanamide, 2-[[2-[(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-4-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-01-0 CAPLUS
 CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-02-1 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[ethyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-16-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[ethyl(phenylamino)methyl]-1H-indol-


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-19-0 CAPLUS
 CN Butanamide, 2-[[2-[(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 562081-25-8 CAPLUS
 CN Benzenesulfonamide, 4-[[2-[(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 562081-26-9 CAPLUS
 CN Benzenepropanamide, alpha-[[2-[(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-27-0 CAPLUS
CN 1H-Indole-3-propanamide, α-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]aminol-, (aS) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-28-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylamino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-31-6 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-61-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-methylpropyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-63-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 562081-64-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-32-7 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-59-8 CAPLUS
CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-60-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[2-

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-67-8 CAPLUS
CN Glycine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 562081-83-8 CAPLUS
CN 1H-Indole-5-carboxamide, N-[[1S]-2-amino-1-[(ethylphenylamino)methyl]-2-oxoethyl]-2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-88-3 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1R)-1-phenylethyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-89-4 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[(methyl[(1S)-1-phenylethyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-90-7 CAPLUS
 CN Piperazine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 562081-91-8 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562081-94-1 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-(ethylphenylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 562081-95-2 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 562081-96-3 CAPLUS
 CN 1H-indole-6-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 562081-92-9 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-methoxyphenyl)methyl]methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562081-93-0 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethylamino)-1-[(ethylphenylamino)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562081-97-4 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-98-5 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-38-6 CAPLUS
 CN 1H-indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(3-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-59-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-((4-chlorophenyl)methyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-68-2 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-85-3 CAPLUS
CN Methanone, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]methyl]-4-piperidinyl-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562082-89-7 CAPLUS
CN Morpholine, 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 562082-90-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-91-1 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-92-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-((4-chlorophenyl)methyl)-N-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562082-86-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[[6-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-87-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[[1R)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562082-88-6 CAPLUS
CN Piperidine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-93-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-94-4 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-95-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[[2-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562082-96-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine,
7-[5-[[[(2-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-97-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl][3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-98-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl][4-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-04-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 562083-10-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[4-(trifluoromethyl)phenoxy]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-34-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[phenylthio]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-35-6 CAPLUS


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-00-5 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-01-6 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl][2-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-02-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-furanyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 4-Piperidinone,
1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 562083-36-7 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[1-oxido-4-thiomorpholinyl]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-37-8 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[phenylmethoxy]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-39-0 CAPLUS
CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[12-phenylethenyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-41-4 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
2-methyl-7-[(5-(2-phenylethyl)-1H-indol-2-
yl)]- (9CI) (CA INDEX NAME)




RN 562083-42-5 CAPLUS
CN 1H-indole-5-methanol, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-
(9CI) (CA INDEX NAME)




RN 562083-43-6 CAPLUS
CN L-Alanine,
N-[(2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-
5-yl)carbonyl]-3-(ethylphenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562083-50-5 CAPLUS
CN Cyclohexanone,
4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-
indol-5-yl]methyl]methylamino]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 562083-74-3 CAPLUS
CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-
indol-5-yl]methyl]methylamino]-1-methyl- (9CI) (CA INDEX NAME)




RN 562083-83-4 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfonyl)methyl]-1H-
indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-84-5 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfonyl)methyl]-1H-
indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-44-7 CAPLUS
CN Benzamide,
N-[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-
5-yl]methyl-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-46-9 CAPLUS
CN Benzamide,
N-[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-
5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-49-2 CAPLUS
CN Cyclohexanone, 4-[[[2-(5-amino-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-
yl]methyl]methylamino]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-85-6 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[5-[(cyclohexyloxy)methyl]-1H-indol-2-
yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-87-8 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine,
7-[5-[(cyclohexylsulfonyl)methyl]-1H-
indol-2-yl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 562083-90-3 CAPLUS
CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(3-cyclohexen-1-
yl)methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 562083-94-7 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine,
 7-[5-(2-cyclohexylethyl)-1H-indol-2-yl]-
 2-methyl- (9CI) (CA INDEX NAME)




RN 562083-98-1 CAPLUS
 CN 1H-indole-5-carboxylic acid,
 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-
 7-yl)- (9CI) (CA INDEX NAME)




RN 562083-99-2 CAPLUS
 CN 1H-imidazo[4,5-b]pyridine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 562084-03-1 CAPLUS
 CN 1H-imidazo[4,5-b]pyridine-2,5-diamine, 7-(1H-indol-2-yl)- (9CI) (CA
 INDEX NAME)




RN 562084-04-2 CAPLUS
 CN 5H-imidazo[4,5-b]pyridin-5-one, 1,4-dihydro-2-methyl-7-[[methyl(phenylmethyl)aminomethyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




IT 561307-19-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of indolydeazapurines for use in pharmaceutical compns.)

for the treatment of inflammatory, autoimmune and proliferative diseases)


RN 561307-19-5 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-1H-indol-2-yl]-2-methyl- (9CI)
 (CA INDEX NAME)




L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 562084-00-8 CAPLUS
 CN Carbamic acid, [7-(1H-indol-2-yl)-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl
 ester (9CI) (CA INDEX NAME)



RN 562084-01-9 CAPLUS
 CN 1H-imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)



RN 562084-02-0 CAPLUS
 CN 2H-imidazo[4,5-b]pyridin-2-one, 5-amino-1,3-dihydro-7-(1H-indol-2-yl)-
 (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT